AEterna Zentaris Inc (NASDAQ:AEZS)

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.